1. Australia Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Genetic Signatures Ltd.

Genetic Signatures Ltd.

AASX:GSS
0.09
AUD
+0.00
(+2.38%)
-0.06EPS
15.22MMarket Cap
Feb 16Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
- -
0.02
0.03
0.02
0.03
0.05
0.09
0.19
0.24
0.15
0.06
0.07
0.06
Basic EPS, GAAP
- -
-0.05
-0.04
-0.03
-0.03
-0.03
-0.02
0.01
0.02
-0.1
-0.11
-0.09
-0.06
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.23
0.09
0.07
0.15
0.13
0.1
0.31
0.34
0.37
0.29
0.28
0.22
0.16
Tangible Book Value per Share
0.23
0.09
0.07
0.15
0.13
0.1
0.31
0.33
0.36
0.25
0.25
0.22
0.16
Basic Weighted Avg Shares
70
52
72
98
106
106
130
146
147
147
165
227
227
Sales/Revenue/Turnover
- -
1
2
2
3
5
11
28
35
21
10
16
14
Operating Margin (%)
- -
-297.78
-249.75
-242.7
-198.47
-118.33
-44.06
4.8
8.09
-69.04
-228.68
-116.23
-122.76
Depreciation Expense
- -
- -
- -
- -
1
- -
1
1
2
2
2
2
2
Net Income, GAAP
- -
-3
-3
-3
-3
-3
-2
2
3
-14
-18
-20
-14
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-254.88
-165.84
-156.47
-114.57
-71.76
-18.52
6.21
8.65
-65.79
-182.9
-126.44
-96.91
Working Capital
16
6
5
16
12
9
43
43
46
30
47
44
33
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
Total Equity
16
7
5
16
13
11
46
49
55
43
61
50
36
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
2.82
5.48
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
3.72
5.89
- -
- -
- -
- -
Return on Common Equity (%)
- -
-22.89
-51.52
-30.87
-22.16
-29.14
-7.38
3.69
5.88
-28.76
-34.34
-36.16
-32.64

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
53%
-2.99%
-28.69%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-68.47%
-95%
-30.33%
Sales/Revenue/Turnover
38.99%
-3.01%
-9.1%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
10
2025
- -
- -
16
2026
- -
- -
14

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.11
2025
- -
- -
-0.09
2026
- -
- -
-0.06

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Maria Julianna Halasz
Full Time Employees
117
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Heart Research Institute Newtown NSW Australia 2042
IPO Date
Mar 30, 2015
Website
geneticsignatures.com
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Genetic Signatures Limited (ASX:GSS) develops and commercializes molecular diagnostics products utilizing its proprietary 3base platform technology for multiplex real-time PCR assays that detect infectious pathogens with high specificity and rapid throughput; the company manufactures and sells a suite of EasyScreen branded detection kits including EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection Kit, EasyScreen Viral Meningitis Detection Kit, EasyScreen Gastrointestinal Parasite Detection Kit, respiratory pathogen kits, SARS-CoV-2 kits, atypical respiratory kits, enteric bacteria kits, enteric viral kits, enteric protozoan kits, and others for routine screening in hospitals, pathology labs, and research settings. Founded in 2001 and headquartered in Newtown, Sydney, Australia, the company operates globally across the Asia Pacific, Europe, Middle East and Africa (EMEA), and Americas regions, with facilities including a production site in Maroubra, Australia; BioHub Birmingham in the United Kingdom; and Los Angeles BioLabs in the United States to support R&D, manufacturing, training, and regional expansion. In recent developments, Genetic Signatures reported 136% revenue growth to AU$8.5 million in the first half of FY25 driven by strong respiratory sales in Australia, secured its first U.S. commercial contract in February 2025, shifted strategic focus from internal instrument development to customizing commercial automated solutions for cost reduction and faster market entry, expanded promotion of its FDA 510(k)-cleared EasyScreen Gastrointestinal Parasite Detection Kit, announced a strategic partnership with Tecan and Repado in July 2025, and released its 2025 Annual Report detailing full-year financial results and performance highlights.